Goal
To provide neuro-oncologists, neurosurgeons, radiation oncologists, and other medical oncologists with up-to-date information on the treatment and management of patients with high-grade gliomas.

Target Audience
This activity is designed for neuro-oncologists, neurosurgeons, radiation oncologists, and other medical oncologists. No prerequisites required.

Learning Objectives
Upon the conclusion of this activity, the participant should be able to:

• Describe the role of surgical resection for patients with recurrent high-grade glioma.
• Apply genetic and other predictors of disease course glioma to individualize therapy.
• Evaluate emerging evidence for the best treatment of patients with glioma.

Accreditation Statement
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The estimated time to complete this educational activity: 2 hours.

Release date: April 15, 2010. Expiration date: April 15, 2012.

Full Disclosure Policy Affecting CME Activities:
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine to require the disclosure of the existence of any relevant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Course Director and Participating Faculty reported the following:

COURSE DIRECTOR

Alessandro Olivi, MD
Professor of Neurosurgery and Oncology
Johns Hopkins University School of Medicine
Baltimore, Maryland
Dr Olivi reports having no relationships with commercial interests related to this activity.

PARTICIPATING FACULTY

Jaishri Blakeley, MD
Assistant Professor of Neurology, Oncology, and Neurosurgery
Johns Hopkins University School of Medicine
Baltimore, Maryland
Dr Blakeley reports having no relationships with commercial interests related to this activity.

Allen K. Sills, MD, FACS
Associate Professor, Department of Neurological Surgery
Vanderbilt University School of Medicine
Nashville, Tennessee
Dr Sills reports having no relationships with commercial interests related to this activity.

Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution that receives the grant, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

Off-Label Product Discussion: The audience is advised that presentations in this CME activity contain reference(s) to unlabeled or unapproved uses of drugs or devices:

Dr Blakeley—CPT-11, gefitinib, talampanel.

All other faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs or devices.

Disclaimer Statement
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of the Johns Hopkins University School of Medicine name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.

This activity is supported by an educational grant from Schering-Plough Corporation.